{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-052220","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.607875+00:00","generated_at":"2026-05-20T14:04:19.896231+00:00","sec_items":["5.07","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Verastem reports 83% ORR for avutometinib+defactinib in front-line metastatic PDAC","bullets":["Dose level 1 (RP2D) achieved 83% ORR (10/12 partial responses) in RAMP 205 trial of frontline metastatic pancreatic cancer.","Across all 5 dose cohorts, 92% (48/52) of evaluable patients showed tumor reduction.","Company plans to start registrational Phase 3 trial in front-line metastatic PDAC in 2026.","No new safety signals; adverse events consistent with previously reported profile.","R&D webcast on June 2, 2025 to discuss RAMP 205 data and VS-7375 KRAS G12D inhibitor data."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-052220","json":"https://secwatch.observer/filing/0001104659-25-052220.json","markdown":"https://secwatch.observer/filing/0001104659-25-052220.md","text":"https://secwatch.observer/filing/0001104659-25-052220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925052220/0001104659-25-052220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925052220/tm2516049d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T14:04:19.896231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}